Altium CEO Jacob Gottlieb Continues On His Journey To Improve Medical Treatments For Patients
Jacob Gottlieb, MD, CFA, PRMIA is the founder of Altium Capital. The firm a healthcare-focused fund located in New York, New York. The primary objective of the company is to identify opportunities for investments centered around growth companies in the sector. Altium Capital was established in 2018.
Dr. Gottlieb is an entrepreneur with a long history of successful endeavors. His interest lies in improving the healthcare industry by funding the development of new and advanced treatments for patients. Two such companies that met Gottlieb’s criteria were Oramed Pharmaceuticals and the Amarin Corporation. The initial investment decision was made in Oramed, and Altium acquired a 5.61% stake in the company. They are responsible for an innovative advance in the form of an oral medication, as opposed to an injectable treatment, for individuals who are afflicted with diabetes. The insulin capsules that are now available are known as ORMD-0801 and ORMD-0901 (exenatide). The Oramed team consists of experienced pharmaceutical experts.
Amarin operates out of Bedminster, NJ and its corporate headquarters in Dublin. The corporation has as its focus the improvement and development of cardiovascular drug treatments. Amarin is an innovative company in the healthcare industry. They have developed a well-tested new drug, namely Vascepa (AMR-101). It has been FDA approved and is available as a prescription drug on the market. Vascepa received approval in 2012.
Jacob Gottlieb and Altium Capital work out of the same office as Stuart Weisbrod, another man known broadly for his expertise in healthcare. Years earlier, he and Jacob were colleagues at Merlin BioMed Group. In 2005, Jacob Gottlieb founded a hedge fund management firm named Visium Asset Management. It was a global enterprise with 200 employees. Visium became the subject of an insider-trading investigation and was eventually shut down. Jacob Gottlieb was never charged with any wrongdoings.
Comments are closed.